<div><div></div><div>Horizon Space Acquisition II Corp. reported net income of $1.81M for fiscal 2025, up from $143K in fiscal 2024, according to its 10-K summary. The company had no commercial operations or revenues prior to completing a business combination and continues to prepare for its transition to an operating public company. Financial Highlights <ul><li>Net income: $1.81M for FY 2025, compared with $143K in FY 2024.</li><li>Diluted earnings per share: Not disclosed in the cited sections.</li><li>Revenue: Not disclosed in the cited sections.</li></ul> Business Highlights <ul><li>Business combination: Entered a definitive agreement to merge with SL Bio Ltd., advancing from a SPAC to an operating company under the combined public company (PubCo).</li><li>Capital deployment: IPO proceeds of $69M were placed in trust to fund the acquisition and post-combination operations.</li><li>Operational status: Prior to the combination the company had no commercial operations or revenues; activities were focused on target identification and due diligence.</li><li>Public listing transition: Units were separated for trading (HSPT/HSPTR); PubCo ordinary shares are expected to list on Nasdaq after closing.</li><li>Extension &amp; continuity plans: The company secured multiple short-term trust deposits and amendments to extend its combination period and support completion of the transaction.</li></ul>Original SEC Filing: Horizon Space Acquisition II Corp. [ HSPT ] - 10-K - Apr. 08, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

LABU

HSPT

Horizon Space Acquisition II Corp. reported a net income of $1.81M for FY 2025, a significant increase from $143K in FY 2024, as per its 10-K summary. The company, which had no prior commercial operations, is transitioning to an operating public company following a merger with SL Bio Ltd. IPO proceeds of $69M are in trust for the acquisition. The company has secured short-term trust deposits to extend its combination period and is preparing for a Nasdaq listing after the merger's completion.

TradingView

Direxion S&P Biotech Bull 3X

Horizon Space Acquisition II

iShares Biotechnology ETF

VanEck Biotech ETF

Mustang Bio

Invesco Nasdaq Biotechnology ETF

BioLife Solutions

Biolife4d Corp

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Horizon Space Acquisition II Corp. FY 2025: Net income $1.81M — 10-K Summary